Pharma giant Johnson & Johnson recently announced that it would acquire all outstanding shares of biopharmaceutical company Intra-Cellular Therapies for a total equity value of approximately $14.6 billion. Biotech bigwig Biogen made an unsolicited, non-binding proposal offer to acquire Sage Therapeutics shares that it does not already own for $7.22 per share.